Faron Pharmaceuticals: Activates EUR10m bond tranche - Redeye

Redeye comments on Faron’s decision to trigger the second €10m tranche of the Heights Capital Management convertible bond. This move was expected following the positive phase II readout from the BEXMAB study. We view the financing as a necessary step to secure operational continuity ahead of the upcoming registrational trials with bexmarilimab.

Länk till analysen i sin helhet: https://www.redeye.se/research/1140551/faron-pharmaceuticals-activates-eur10m-bond-tranche?utm_source=finwire&utm_medium=RSS